

---

Vision 3

# SIS 10160 User Guide



---

Copyright © INPS Ltd

The Bread Factory, 1A Broughton Street, Battersea, London, SW8 3QJ

T: +44 (0) 207 501700 F:+44 (0) 207 5017100 W: [www.inps.co.uk](http://www.inps.co.uk)

## Copyright Notice

© 2013 INPS  
All Rights Reserved.

*No part of this document may be photocopied, reproduced, stored in a retrieval system or transmitted in any form or by any means, whether electronic, mechanical, or otherwise, without the prior written permission of INPS.*

*No warranty of accuracy is given concerning the contents of the information contained in this publication. To the extent permitted by law, no liability (including liability to any person by reason of negligence) will be accepted by INPS, its subsidiaries or employees for any direct or indirect loss or damage caused by omissions from or inaccuracies in this document.*

*INPS reserves the right to change without notice the contents of this publication and the software to which it relates.*

*Product and company names herein may be the trademarks of their respective owners.*

**INPS Ltd.**

The Bread Factory  
1a Broughton Street  
London  
SW8 3QJ

Website: [www.inps.co.uk](http://www.inps.co.uk)

---

# Contents

---

<b>SIS 10160</b>	<b>1</b>
<b>What's New</b>	<b>1</b>
<b>PHE Pneumococcal PPV Reporting 2013</b>	<b>1</b>
<b>QOF v24 Changes</b>	<b>1</b>
Asthma	1
Atrial Fibrillation	1
Cancer	2
CHD	3
CKD	4
COPD	4
CVD PP	5
Cytology	6
Dementia	6
Depression	7
Diabetes	7
Epilepsy	8
Heart Failure	9
Hypertension	9
Learning Disabilities	9
Mental Health	9
Obesity	10
Osteoporosis: Secondary prevention of fragility fractures	10
Peripheral Arterial Disease (PAD)	11
Palliative Care	11
Records	11
Sexual Health	12
Smoking	12
Stroke	13
Hypothyroid	13
Data Quality audits	13
<b>INDEX</b>	<b>15</b>

---



# SIS 10160

---

## What's New

SIS 10160 brings the 2013 schedule for *Public Health England Pneumococcal* reporting and the changes for *QOF version 24*.

---

## PHE Pneumococcal PPV Reporting 2013

SIS 10160 delivers the new reporting schedule for Pneumococcal PPV 2013:

- Dates of birth for catchment have been moved forward a year.
- The reporting time frame has moved from 2011-12 to 2012-13.

---

## QOF v24 Changes

The following changes have been made to the Quality Outcome Framework for Version 24:

### Asthma

**Smoking habit** updated to include new codes from October 2012 Read code release:

- 137n. Total time smoked
- 137o. Waterpipe tobacco consumption

### Atrial Fibrillation

**Warfarin** contraindications: expiring updated to included the new codes from October 2012 Read code release:

- 8I2o. Dabigatran contraindicated
- 8IES. Dabigatran declined
- 8I611 Dabigatran not indicated
- 8I7R. Dabigatran not tolerated

### Cancer

**Cancer diagnostic** codes updated to include new codes from October 2012 Read code release:

- B36.. Local recurrence of malignant tumour of breast \*

B498. Local recurrence of malignant tumour of urinary bladder \*  
K1323 Acquired renal cyst with neoplastic change  
K01w1 Drash syndrome

**Cancer diagnostic** codes updated to include new codes from April 2012 Read code release:

B5770 Secondary malignant neoplasm of liver intrahepatic bile duct \*

B595. Malignant tumour of unknown origin \*

B617. Nodular lymphocyte predominant Hodgkin lymphoma \*

B618. Nodular sclerosis classical Hodgkin lymphoma \*

B619. Mixed cellularity classical Hodgkin lymphoma \*

B61A. Lymphocyte depleted classical Hodgkin lymphoma \*

B61B. Lymphocyte-rich classical Hodgkin lymphoma \*

B61C. Other classical Hodgkin lymphoma \*

B627F Extranod marg zone B-cell lymphom mucosa-assoc lymphoid tiss \*

B627G Mediastinal (thymic) large B-cell lymphoma \*

B628. Follicular lymphoma \*

B6280 Follicular lymphoma grade 1 \*

B6281 Follicular lymphoma grade 2 \*

B6282 Follicular lymphoma grade 3 \*

B6283 Follicular lymphoma grade 3a \*

B6284 Follicular lymphoma grade 3b \*

B6285 Diffuse follicle centre lymphoma \*

B6286 Cutaneous follicle centre lymphoma \*

B6287 Other types of follicular lymphoma \*

B629. Multifocal multisystemic dissem Langerhans-cell histiocytosi \*

B62A. Sarcoma of dendritic cells \*

B62B. Multifocal and unisystemic Langerhans-cell histiocytosis \*

B62C. Unifocal Langerhans-cell histiocytosis \*

B62D. Histiocytic sarcoma \*

B62E. T/NK-cell lymphoma \*

B62E0 Mature T/NK-cell lymphoma \*

B62E1 Anaplastic large cell lymphoma, ALK-positive \*

B62E2 Anaplastic large cell lymphoma, ALK-negative \*

B62E3 Cutaneous T-cell lymphoma \*

B62E4 Extranodal NK/T-cell lymphoma, nasal type \*

B62E5 Hepatosplenic T-cell lymphoma \*

B62E6 Enteropathy-associated T-cell lymphoma \*

B62E7 Subcutaneous panniculitic T-cell lymphoma \*

B62E8 Blastic NK-cell lymphoma \*

B62E9 Angioimmunoblastic T-cell lymphoma \*  
 B62EA Primary cutaneous CD30-positive T-cell proliferations \*  
 B62Ew Other mature T/NK-cell lymphoma \*  
 B62F. Nonfollicular lymphoma \*  
 B62F0 Small cell B-cell lymphoma \*  
 B62F1 Mantle cell lymphoma \*  
 B62F2 Lymphoblastic (diffuse) lymphoma \*  
 B62Fy Other non-follicular lymphoma \*  
 B6304 Solitary plasmacytoma \*  
 B6400 B-cell acute lymphoblastic leukaemia \*  
 B6410 B-cell chronic lymphocytic leukaemia \*  
 B64y3 B-cell prolymphocytic leukaemia \*  
 B64y4 T-cell prolymphocytic leukaemia \*  
 B64y5 Adult T-cell lymphoma/leukaemia (HTLV-1-associated) \*  
 B6500 Acute myeloid leukaemia with 11q23 abnormality \*  
 B6501 Acute myeloid leukaemia with multilineage dysplasia \*  
 B6511 Chronic myeloid leukaemia, BCR/ABL positive \*  
 B6513 Atypical chronic myeloid leukaemia, BCR/ABL negative \*  
 B654. Acute myeloblastic leukaemia \*  
 B663. Acute monoblastic leukaemia \*  
 B676. Acute erythroid leukaemia \*  
 B693. Juvenile myelomonocytic leukaemia \*

\*Note that these codes are captured within the existing B34..-B6z0. Range and therefore do not show separately in the cluster.

**Cancer diagnostic** codes to *exclude* the new October 2012 Read code release from the B34..-B6:

B677. Myelodysplastic and myeloproliferative disease

## CHD

**Warfarin contraindications** updated (see above under Atrial Fibrillation)

**Flu vaccination** codes updated to include the new code from October 2012 Read code release:

65ED0 Seasonal influenza vaccination given by pharmacist.

**AII antagonist prescription** codes updated to include the hierarchy bkJ..% following the release of new codes in the October 2012 Read code release. This hierarchy contains the codes below:

bkJ.. AZILSARTAN

bkJ1. EDARBI 20mg tablets

bkJ2. AZILSARTAN MEDOXOMIL 20mg tablets

bkJ3. EDARBI 40mg tablets

- bkJ4. AZILSARTAN MEDOXOMIL 40mg tablets
- bkJ5. EDARBI 80mg tablets
- bkJ6. AZILSARTAN MEDOXOMIL 80mg tablets

## CKD

**Albumin:creatinine and Protein:creatinine ratio for CKD** updated to include the following code after a review of the cluster:

46TD. Urine microalbumin:creatinine ratio

**Hypertension diagnosis** codes updated to *exclude* the following code released in the October 2012 Read code release:

G27.. Hypertension resistant to drug therapy

**Hypertension diagnosis** codes updated to include the following code released in the October 2012 Read code release:

G25.. Stage 1 hypertension (NICE - Nat Ins for Hth Clin Excl 2011) \*

G26.. Severe hypertension (Nat Inst for Health Clinical Ex 2011) \*

G28.. Stage 2 hypertension (NICE - Nat Ins for Hth Clin Excl 2011) \*

\* Note that these codes are captured within the existing G24.. - G2z.. range and therefore do not show separately in the cluster.

## COPD

**Flu vaccination codes** updated (see above under CHD)

**Indicator COPD13** – The percentage of patients with COPD who have had a review, undertaken by a healthcare professional, including an assessment of breathlessness using the MRC dyspnoea score in the preceding 15 months.

Indicator COPD13 - Change made to correct additional notes explaining how **Denominator Rule 2** is working:

From:

Rule 2: The aim of this rule is to identify any patient that has an accepted 'COPD Exception' Read Code recorded. If the patient has an accepted 'COPD Exception' Read Code recorded in the last 15 months, the patient should not be included in the denominator.

To:

Rule 2: The aim of this rule is to identify any patient that 'recently registered' at the practice. If the patient has registered at the practice in the last 3 months, the patient should not be included in the denominator.

**Indicator COPD13** – Change made to correct additional notes explaining how **Denominator Rule 3** is working:

From:

Rule 3: The aim of this rule is to identify any patient that has an accepted 'Spirometry exception Read Code' recorded. If the patient has an accepted 'Spirometry exception Read Code' recorded in the last 15 months, the patient should not be included in the denominator.

To:



Rule 3: The aim of this rule is to identify any patient that has an accepted 'COPD Exception' Read Code recorded. If the patient has an accepted 'COPD Exception' Read Code recorded in the last 15 months, the patient should not be included in the denominator.

**Indicator COPD8** – The percentage of patients with COPD who have had influenza immunisation in the preceding 1 September to 31 March.

Indicator COPD8 – change made to correct additional notes explaining how **Denominator Rule 2** is working:

From:

Rule 2: The aim of this rule is to identify any patient that has an accepted 'COPD Exception' Read Code recorded. If the patient has an accepted 'COPD Exception' Read Code recorded in the last 15 months, the patient should not be included in the denominator.

To:

Rule 2: The aim of this rule is to identify any patient that 'recently registered' at the practice. If the patient has registered at the practice in the last 3 months, the patient should not be included in the denominator.

**Indicator COPD8** – Change made to correct additional notes explaining how **Denominator Rule 3** is working:

From:

Rule 3: The aim of this rule is to identify any patient that has an accepted 'Spirometry exception Read Code' recorded. If the patient has an accepted 'Spirometry exception Read Code' recorded in the last 15 months, the patient should not be included in the denominator.

To:

Rule 3: The aim of this rule is to identify any patient that has an accepted 'COPD Exception' Read Code recorded. If the patient has an accepted 'COPD Exception' Read Code recorded in the last 15 months, the patient should not be included in the denominator.

## CVD PP

Change in **Hypertension** diagnosis codes (see above under CKD)

**Diabetes** diagnosis codes updated to include the new code from the October 2012 Read code release:

PkyP. Diab insipidus, diab mell, optic atrophy and deafness

**PVD** diagnostic codes updated to include new code from the October 2012 Read code release:

G734. Peripheral arterial disease

**TIA** diagnosis codes updated to include the new code from the October 2012 Read code release:

G657. Carotid territory transient ischaemic attack \*\*

\*\* Note that this code is captured within the existing G656. - G65zz range therefore does not show separately in the cluster.

**Cardiovascular disease risk assessment exception** codes updated to include the new codes released in the October 2012 Read code release:

8IEV. QRISK2 cardiovascular disease risk assessment declined

9NSB. Unsuitable for QRISK2 cardiovascular disease risk assessment

## Cytology

There are no changes in version 24 of the Business Rules which affect the cytology ruleset.

## Dementia

**Indicator DEM4** – Exclusion notes in the Overview section amended to read:

Consideration has to be made for those patients who have been diagnosed with dementia in the previous QOF financial year AND have successful recordings for all the tests in the previous QOF Financial Year because practices will have been rewarded for the indicator in that earlier year. This rule is in place to prevent duplicate payments.

Indicator DEM4 – rule updated to the below to correct **Denominator Rule 3:**

If the date of the FBC is less than the reference date minus 12 months

AND

If the date of the calcium test is less than the reference date minus 12 months

AND

If the date of the glucose test is less than the reference date minus 12 months

OR

If the date of the IFC HbA1c test is less than the reference date minus 12 months

AND

If the date of the renal tests is less than the reference date minus 12 months

AND

If the date of the liver tests is less than the reference date minus 12 months

AND

If the date of the thyroid function tests is less than the reference date minus 12 months

AND

If the date of the serum vitamin B12 test is less than the reference date minus 12 months

AND

If the date of the folate levels test is less than the reference date minus 12 months

AND

The date of the dementia diagnosis is less than the reference date of 12 months

**Indicator DEM4** – change made to additional notes to better explain how **Denominator Rule 3** is working:

From:

Rule 3: The objective of this rule is to identify patients who have successful recordings for all the tests in the previous QOF Financial Year.

If the patient has recordings of all the tests (FBC, calcium test, glucose test, renal test, liver test, thyroid function test, serum vitamin B12, folate levels test) in the previous QOF financial year and they are all within the appropriate timeframe from diagnosis they are rejected from the denominator. The practice will have been rewarded for this indicator in the previous QOF financial year.

If not they are passed on to the next rule.

To:

Rule 3: The objective of this rule is to identify patients who have a dementia diagnosis in the previous QOF Financial Year and have successful recordings for all the tests in the previous QOF Financial Year.

If the patient was diagnosed with dementia in the previous QOF Financial Year, has recordings of all the tests (FBC, calcium test, glucose test, renal test, liver test, thyroid function test, serum vitamin B12, folate levels test) in the previous QOF financial year and they are all within the appropriate timeframe from diagnosis they are rejected from the denominator. The practice will have been rewarded for this indicator in the previous QOF financial year.

If not they are passed on to the next rule.

## Depression

Diagnostic codes for **diabetes mellitus** updated to include the new code from the October 2012 Read code release:

PkyP. Diab insipidus, diab mell, optic atrophy and deafness

## Diabetes

Diagnostic codes for **diabetes mellitus** updated to include the new code from the October 2012 Read code release:

PkyP. Diab insipidus, diab mell, optic atrophy and deafness

**Microalbuminuria testing** codes updated to include the following code after review of the cluster:

46TD. Urine microalbumin:creatinine ratio

**Flu vaccination** codes updated:

65ED0 Seasonal influenza vaccination given by pharmacist

**BMI** codes updated to include the following new code from the October 2012 Read code release:

22KB. Baseline body mass index \*

\* Note that this code is captured within the existing 22K..% hierarchy therefore does not show separately in the cluster.

**BMI** codes updated to *exclude* the following new October 2012 Read code release, from the 22K..% hierarchy:

- 22K90 Baseline body mass index centile
- 22KA. Target body mass index

**Foot Risk classification** codes updated to include the new codes from the October 2012 Read code release:

- 2G5d. O/E – Left diabetic foot at increased risk
- 2G5e. O/E – Right diabetic foot at increased risk

**Proteinuria** codes updated to include the new code from the October 2012 Read code release:

- K08yA Proteinuric diabetic nephropathy

**AII antagonist prescription** codes updated to include the hierarchy bkJ..% following the release of new codes in the October 2012 Read code release. This hierarchy contains the codes below:

- bkJ.. AZILSARTAN
- bkJ1. EDARBI 20mg tablets
- bkJ2. AZILSARTAN MEDOXOMIL 20mg tablets
- bkJ3. EDARBI 40mg tablets
- bkJ4. AZILSARTAN MEDOXOMIL 40mg tablets
- bkJ5. EDARBI 80mg tablets
- bkJ6. AZILSARTAN MEDOXOMIL 80mg tablets

## Epilepsy

**Epilepsy** diagnostic codes updated to exclude the new code from the October 2012 Read code release, by excluding from the F25..% hierarchy:

- F25G. Severe myoclonic epilepsy in infancy

**Drug treatments for epilepsy** to include the new codes from the October 2012 Read code release:

- dnr4. INOVELON 40mg/mL oral suspension \*
- dntE. LACOSAMIDE 10mg/1mL sugar free liquid \*
- dnp9. LYRICA 20mg/1mL oral solution \*
- dnpr. PREGABALIN 20mg/1mL oral solution \*
- dnrw. RUFINAMIDE 40mg/mL oral suspension \*
- dntD. VIMPAT 10mg/1mL syrup \*

\* Note that these codes are captured within the existing dn...% hierarchy and therefore do not show separately in the cluster.

**Sterilisation** codes updated to ensure consistency, from 7E1c to 7E1C.%:

**Hysterectomy and equivalent** codes updated to include the below code following a review of the cluster:

- L3985 Delivery by caesarean hysterectomy

## Heart Failure

**Echocardiogram** codes updated include the new codes from the October 2012 Read code release:

7P0H6 Contrast echocardiography

8A544 Monitoring of cardiac output using echocardiography

**AII antagonist** codes updated (see above under Diabetes)

## Hypertension

**Hypertension** diagnosis codes updated to *exclude* the following code released in the October 2012 Read code release:

G27.. Hypertension resistant to drug therapy

**Hypertension** diagnosis codes updated include the new codes from the October 2012 Read code release:

G25.. Stage 1 hypertension (NICE - Nat Ins for Hth Clin Excl 2011) \*

G26.. Severe hypertension (Nat Inst for Health Clinical Ex 2011) \*

G28.. Stage 2 hypertension (NICE - Nat Ins for Hth Clin Excl 2011) \*

\* Note that these codes are captured within the existing G24.. - G2z.. range and therefore do not show separately in the cluster.

## Learning Disabilities

**Hypothyroidism treatment** codes updated include the new codes from the October 2012 Read code release:

f92D. ELTROXIN 25micrograms/5mL oral solution \*

f92E. ELTROXIN 50micrograms/5mL oral solution \*

f92F. ELTROXIN 100micrograms/5mL oral solution \*

\* Note that these codes are captured within the existing f9...% hierarchy and therefore do not show separately in the cluster.

## Mental Health

**Hypertension** diagnosis codes updated – see above under Hypertension.

**Diabetes** diagnosis codes updated – see above under Diabetes.

**BMI** codes updated – see above under Diabetes

**PVD** diagnostic code updated to include new code from October 2012 Read code release:

G734. Peripheral arterial disease

**Stroke or TIA** codes updated to include new code from October 2012 Read code release:

G657. Carotid territory transient ischaemic attack

Note that this code is captured within the existing G656. - G65zz range therefore does not show separately in the cluster.

## Obesity

**BMI** diagnostic codes (with an associated BMI value) updated to include new code from the October 2012 Read code release:

22KB. Baseline body mass index

## Osteoporosis: Secondary prevention of fragility fractures

**Bone-sparing agent cat1 contraindications: expiring**, codes updated to include the new codes from the October 2012 Read code release:

8I2V3 Alendronic acid contraindicated

8I3e3 Alendronic acid declined

8I6R3 Alendronic acid not indicated

8I7E3 Alendronic acid not tolerated

8I2V2 Disodium etidronate contraindicated

8I3e2 Disodium etidronate declined

8I6R2 Disodium etidronate not indicated

8I7E2 Disodium etidronate not tolerated

8I2V0 Ibandronic acid contraindicated

8I3e0 Ibandronic acid declined

8I6R0 Ibandronic acid not indicated

8I7E0 Ibandronic acid not tolerated

8I2V4 Risedronate sodium contraindicated

8I3e4 Risedronate sodium declined

8I6R4 Risedronate sodium not indicated

8I7E4 Risedronate sodium not tolerated

**Bone sparing agent cat3 contra-indications: expiring**, codes updated to include the new codes from the October 2012 Read Code release:

8I2p. Denosumab contraindicated

8IEW. Denosumab declined

8I612 Denosumab not indicated

8I7S. Denosumab not tolerated

**Bone sparing agent cat1 contra-indications: persistent**, codes updated to include the new codes from the October 2012 Read Code release:

14LT3 H/O alendronic acid allergy

14LT4 H/O risedronate sodium allergy

**Bone sparing agent cat3 contra-indications: persistent**, codes updated to include the new codes from the October 2012 Read Code release:

- 14Lc. H/O denosumab allergy
- 14LT2 H/O disodium etidronate allergy
- 14LT0 H/O ibandronic acid allergy

**Bone sparing agent codes** - Removal of the below hierarchy of codes following a review of the cluster and advice from NICE:

fn2..%

## Peripheral Arterial Disease (PAD)

**PAD** diagnostic codes updated to include new code from the October 2012 Read code release:

- G734. Peripheral arterial disease

## Palliative Care

Diagnostic codes for **Palliative care register** updated to include new codes from the October 2012 Read code release:

- 9G8.. Ambulance service notified of patient on EoL care register
- 9c0P. Current palliative oncology treatment
- 9c0N. Current supportive care for terminal illness
- 8CMW3 End of life care pathway
- 9K9.. Palliative care handover form completed
- 9367. Patient held palliative care record
- 9c0L0 Planned palliative oncology treatment
- 9c0M. Planned supportive care for terminal illness
- 9NNd. Under care of palliative care specialist nurse
- 8CM16 GSF prognostic indicator stage B (green) - months prognosis \*
- 8CM17 GSF prognostic indicator stage C (yellow) - weeks prognosis \*
- 8CM18 GSF prognostic indicator stage D (red) - days prognosis \*

\* Note that these codes are captured within the existing 8CM1.% hierarchy and therefore do not show separately in the cluster.

**Palliative care** diagnostic codes updated to *exclude* new October 2012 Read code release. This has been achieved by excluding the code from the 8CM1.% hierarchy:

- 8CM15 GSF prognostic indicator stage A (blue) - yr plus prognosis

## Records

There are no changes in version 24.0 of the Business Rules which affect the Records ruleset.

## Sexual Health

**Sexual Health diagnostic codes (IUD)** updated to include the new codes from the October 2012 Read code release:

- pg3A. NOVAPLUS T 380Ag mini intra-uterine contraceptive device \*
- pg3B. NOVAPLUS T 380Ag maxi intra-uterine contraceptive device \*
- pg3C. NOVAPLUS T 380Cu normal intra-uterine contraceptive device \*
- pg3D. NOVAPLUS T 380Cu mini intra-uterine contraceptive device \*
- pg3E. ANCORA 375Cu intra-uterine contraceptive device \*
- pg3F. ANCORA 375Cu intra-uterine contraceptive device \*
- pg3y. COPPER T 380A intra-uterine contraceptive device \*
- pg3z. NOVAPLUS T 380Ag normal intra-uterine contraceptive device \*

\* Note that these codes are captured within the existing pg3..% hierarchy therefore do not show separately in the cluster.

**Sexual Health diagnostic codes (Progestogen only oral contraception)** updated to include the new codes from the October 2012 Read code release:

- ga92. ESMYA 5mg tablets
- ga9y. ULIPRISTAL ACETATE 5mg tablets

## Smoking

**Hypertension** diagnosis codes updated (see above under Hypertension)

**Diabetes mellitus** codes updated (see above under Diabetes)

**PAD** diagnostic codes updated (see above under PAD)

**TIA** diagnostic codes updated(see below under Stroke)

**Smoking habit** codes updated to include new code from the October 2012 Read code release:

- 137n. Total time smoked
- 137o. Waterpipe tobacco consumption

**Current smoker** codes to include new code from the October 2012 Read code release:

- 137o. Waterpipe tobacco consumption

**Smoker** codes to include new code from the October 2012 Read code release:

- 137o. Waterpipe tobacco consumption

**Pharmacotherapy** codes updated to include new codes from the October 2012 Read code release:

- du7g. NICORETTE COOLS 2mg lozenges \*\*\*
- du7h. NICORETTE COOLS 4mg lozenges \*\*\*



\*\*\* Note that these codes are captured within the existing du7..% hierarchy therefore do not show separately in the cluster.

## Stroke

**Stroke and/or TIA** diagnostic codes updated to include the new code from the October 2012 Read code release:

G657. Carotid territory transient attack \*

---

Note that this code is captured within the existing G656.-G65zz range and therefore does not show separately in the cluster.

---

**Warfarin contraindications: expiring** codes updated to include new codes from the October 2012 Read code release:

8I2o. Dabigatran contraindicated

8IES. Dabigatran declined

8I611 Dabigatran not indicated

8I7R. Dabigatran not tolerated

**Flu vaccination** codes updated to include the new code from the October 2012 Read code release:

65ED0 Seasonal influenza vaccination given by pharmacist

## Hypothyroid

**Hypothyroidism treatment** codes updated to include the new codes from the October 2012 Read code release:

f92D. ELTROXIN 25micrograms/5mL oral solution \*

f92E. ELTROXIN 50micrograms/5mL oral solution \*

f92F. ELTROXIN 100micrograms/5mL oral solution \*

\* Note that these codes are captured within the existing f9...% hierarchy and therefore do not show separately in the cluster.

## Data Quality audits

New Sections

Quality and Productivity - including A&E, and Consultations.

Problems, Histories and Priorities

Co-Morbidity Registers

Changes to Medicines Managements. Lines now include:

Active repeat masters authorised between 9 and 12 months ago but never issued

Active repeat masters not issued in last 6/9/12 months (excluding never issued)



# Index

---

## A

Asthma • 1  
Atrial Fibrillation • 1

---

## C

Cancer • 2  
CHD • 3  
CKD • 4  
COPD • 4  
Copyright Notice • ii  
CVD PP • 5  
Cytology • 6

---

## D

Data Quality audits • 13  
Dementia • 6  
Depression • 7  
Diabetes • 7

---

## E

Epilepsy • 8

---

## H

Heart Failure • 9  
Hypertension • 9  
Hypothyroid • 13

---

## L

Learning Disabilities • 9

---

## M

Mental Health • 9

---

## O

Obesity • 10  
Osteoporosis  
    Secondary prevention of fragility fractures • 10

---

## P

Palliative Care • 11  
Peripheral Arterial Disease (PAD) • 11  
PHE Pneumococcal PPV Reporting 2013 • 1

---

## Q

QOF v24 Changes • 1

---

## R

Records • 11

---

## S

Sexual Health • 12  
SIS 10160 • 1  
Smoking • 12  
Stroke • 13

---

## W

What's New • 1